JNJ
The setup
Johnson & Johnson is set to report third-quarter fiscal 2027 results on Nov. 12, and Bank of America Securities thinks the company will hit the top line but stumble a bit on earnings. That’s a pretty classic “good news, complicated news” combo: revenue should come in around consensus, but profit may take a hit from IPR&D dilution that the company already warned about.
What BofA is really watching
Analyst Jason Gerberry kept a Neutral rating and bumped his price target from $263 to $278, which is analyst-speak for “this isn’t broken, but I’m not exactly sprinting after it.” The note pointed to a few big moving parts:
- Pharma revenue is expected to grow about 7% year over year
- MedTech is projected to grow about 4%
- Icotyde’s psoriasis launch is getting a bigger sales estimate after BofA’s physician survey
- Oncology launches like Inlexzo and Tecvayli are also in the spotlight
- Talc remains the uninvited guest at the dinner party
Why investors care
Gerberry said J&J disclosed 2026 earnings dilution from IPR&D of 64 cents per share, and most of that should hit in the third quarter. In other words: the business may be moving fine underneath, but accounting and investment spending could make the bottom line look a little wobbly.
He also raised Icotyde’s peak psoriasis sales estimate to $4.5 billion from $2.4 billion, which is a meaningful upgrade. That suggests the market may be underestimating how big that launch could get if the dermatology momentum keeps building.
The big picture
J&J is still doing the classic pharma giant balancing act: launch new drugs, keep MedTech humming, and try not to let one-off costs steal the spotlight. If the company confirms healthy revenue growth while the earnings miss stays contained, investors may shrug and keep moving. If not, well, even blue chips can get treated like a teenager missing curfew.
Big picture: this is less a “sky is falling” moment than a reminder that giant healthcare companies often look messy right before they look boring again.